Our data showed that caffeine-induced reduction of the reversal rate is mimicked by the selective A2AR antagonists istradefylline, an FDA-approved molecule that is currently used in the treatment of PD (45), and ZM241385, as well as by the selective A1R antagonist DPCPX (Fig. 6A–C). Here, ADORA2A is linked to Parkinson disease.